BASEL, SWITZERLAND -- (MARKET WIRE) -- May 18, 2007 -- Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ceftobiprole by its co-development partner Johnson & Johnson Pharmaceutical Research and Development, L.L.C. This submission is for the use of ceftobiprole in the treatment of complicated skin and skin structure infections (cSSSI) including diabetic foot infections. Submissions to other health authorities around the world will follow. Ceftobiprole is a novel anti-MRSA broad-spectrum cephalosporin antibiotic.
